Subcutaneous vs Intravenous Trastuzumab for Patients With ERBB2-Positive Early Breast Cancer: Final Analysis of the HannaH Phase 3 Randomized Clinical Trial

IMPORTANCE: Confirmation of long-term comparability between subcutaneous and intravenous trastuzumab is essential. OBJECTIVE: To evaluate efficacy and safety of subcutaneous trastuzumab compared with that of intravenous trastuzumab for patients with ERBB2 (HER2)–positive early breast cancer after 6...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JAMA Oncol
Hlavní autoři: Jackisch, Christian, Stroyakovskiy, Daniil, Pivot, Xavier, Ahn, Jin Seok, Melichar, Bohuslav, Chen, Shin-Cheh, Meyenberg, Christoph, Al-Sakaff, Nedal, Heinzmann, Dominik, Hegg, Roberto
Médium: Artigo
Jazyk:Inglês
Vydáno: American Medical Association 2019
Témata:
Brief Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6512301/
https://ncbi.nlm.nih.gov/pubmed/30998824
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.0339
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky